Unnamed: 0,title,date,stock,sentiment
31232.0,"The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage",2020-06-07 13:43:00-04:00,ADXS,neutral
31233.0,20 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-05-15 07:33:00-04:00,ADXS,neutral
31234.0,Advaxis Announces Updated Clinical And Biomarker Data From Ongoing Phase 1/2 ADXS-503 Trial In NSCLC,2020-05-14 08:24:00-04:00,ADXS,neutral
31235.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,ADXS,negative
31236.0,17 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-04-22 07:38:00-04:00,ADXS,neutral
31237.0,18 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-03-17 08:58:00-04:00,ADXS,neutral
31238.0,"Advaxis Q1 EPS $(0.15) Down From $2.76 YoY, Sales $3M Down From $19.689M YoY",2020-03-13 09:03:00-04:00,ADXS,neutral
31239.0,52 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-03-09 08:04:00-04:00,ADXS,neutral
31240.0,30 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-03-02 07:41:00-05:00,ADXS,neutral
31241.0,50 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-02-28 08:34:00-05:00,ADXS,neutral
31242.0,46 Stocks Moving in Friday's Pre-Market Session,2020-02-28 07:39:00-05:00,ADXS,neutral
31243.0,Advaxis Announces Updated Clinical Data In Ongoing Phase 1/2 ADXS-503 Trial In NSCLC At I/O 360° Conference,2020-02-27 09:14:00-05:00,ADXS,neutral
31244.0,28 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-02-27 07:40:00-05:00,ADXS,neutral
31245.0,24 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-02-26 08:01:00-05:00,ADXS,neutral
31246.0,Advaxis Announces Clinical Data In Ongoing Phase 1/2 ADXS-503 Trial On NSCLC At ASLC 2020 Targeted Therapies Of Lung Cancer Meeting; 'Was 'safe and tolerable with potential signs of clinical activity in 4 of 7 evaluable patients achieving stable disease',2020-02-20 08:09:00-05:00,ADXS,negative
31247.0,"The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions",2020-02-16 15:03:00-05:00,ADXS,positive
31248.0,Advaxis Announces Updated Survival Data In Phase 1/2 ADXS-PSA Trial At The ASCO Genitourinary Cancers Symposium,2020-02-13 08:09:00-05:00,ADXS,neutral
31249.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,ADXS,negative
31250.0,8 Biotechnology Stocks Moving In Thursday's Pre-Market Session,2020-02-13 07:36:00-05:00,ADXS,neutral
31251.0,13 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-02-13 07:34:00-05:00,ADXS,neutral
31252.0,Advaxis Reports Research Deal With Personalis To Deploy ImmunoID NeXT Platform In ADXS-503 Program,2020-02-11 08:02:00-05:00,ADXS,neutral
31253.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,ADXS,neutral
31254.0,"Advaxis To Present Clinical Data At ASCO Genitourinary Cancers Symposium (Feb 13), IASLC 2020 Targeted Therapies of Lung Cancer Meeting February (Feb. 22) And Immuno-oncology 360° (Feb 27)",2020-01-30 09:41:00-05:00,ADXS,negative
31255.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,ADXS,neutral
31256.0,9 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-22 07:33:00-05:00,ADXS,neutral
31257.0,6 Biotechnology Stocks Moving In Wednesday's Pre-Market Session,2020-01-22 07:33:00-05:00,ADXS,neutral
31258.0,82 Biggest Movers From Yesterday,2020-01-22 04:18:00-05:00,ADXS,neutral
31259.0,Mid-Afternoon Market Update: CSS Industries Surges Following Acquisition News; Advaxis Shares Slide,2020-01-21 15:05:00-05:00,ADXS,positive
31260.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-01-21 12:14:00-05:00,ADXS,neutral
31261.0,Mid-Day Market Update: Dow Falls Over 100 Points; Genprex Shares Spike Higher,2020-01-21 12:07:00-05:00,ADXS,positive
31262.0,Mid-Morning Market Update: Markets Open Lower; Halliburton Beats Q4 Estimates,2020-01-21 10:07:00-05:00,ADXS,negative
31263.0,Advaxis shares are trading lower after the company priced its 10 million share registered direct offering at $1.05 per share.,2020-01-21 09:10:00-05:00,ADXS,positive
31264.0,Advaxis Prices 10M Share Registered Direct Offering At $1.05/Share,2020-01-21 08:33:00-05:00,ADXS,positive
31265.0,Advaxis Inc Says Received Notice From Nasdaq Indicating Co Has Regained Compliance With Nasdaq Listing Rules,2020-01-16 11:35:00-05:00,ADXS,neutral
31266.0,14 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-01-16 07:51:00-05:00,ADXS,neutral
31267.0,21 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-01-10 07:38:00-05:00,ADXS,neutral
31268.0,50 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-08 08:31:00-05:00,ADXS,neutral
31269.0,Advaxis shares are trading higher after the company announced it received FDA clearance of its IND for ADXS-504 in the treatment of prostate cancer.,2020-01-07 08:26:00-05:00,ADXS,negative
31270.0,Advaxis Announces FDA Clearance Of IND For ADXS-504 For Treatment Of Prostate Cancer,2020-01-07 08:02:00-05:00,ADXS,negative
31271.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-01-06 07:38:00-05:00,ADXS,neutral
31272.0,21 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-01-02 07:49:00-05:00,ADXS,neutral
31273.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-30 08:21:00-05:00,ADXS,neutral
31274.0,31 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-12-27 08:13:00-05:00,ADXS,neutral
31275.0,Advaxis shares are trading higher on continued momentum after the company reported FY19 EPS results up from last year.,2019-12-24 11:13:00-05:00,ADXS,positive
31276.0,Advaxis FY19 EPS $(1.09) vs $(19.36) In FY18,2019-12-20 08:01:00-05:00,ADXS,neutral
31277.0,13 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-12-11 07:54:00-05:00,ADXS,neutral
31278.0,41 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-10 08:10:00-05:00,ADXS,neutral
31279.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,ADXS,neutral
31280.0,48 Stocks Moving In Monday's Mid-Day Session,2019-12-09 12:26:00-05:00,ADXS,neutral
31281.0,Advaxis shares are trading higher. Not seeing any news to justify the price action.,2019-12-09 10:25:00-05:00,ADXS,positive
31282.0,Advaxis shares are trading higher in sympathy with the overall market amid a rally in US equities following strong November jobs data.,2019-12-06 10:51:00-05:00,ADXS,positive
31283.0,Advaxis Submits IND Application For ADXS-HOT Drug Candidate For Prostate Cancer,2019-12-03 08:05:00-05:00,ADXS,negative
31284.0,Advaxis shares are trading higher on above-average volume. Not seeing any company-specific news to justify the price action. NOTE: Penny stocks can have volatile price action with no catalyst.,2019-12-02 10:33:00-05:00,ADXS,neutral
31285.0,Advaxis shares are trading higher. Not seeing any news to justify the price action.,2019-11-22 10:28:00-05:00,ADXS,positive
31286.0,13 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-11-20 07:45:00-05:00,ADXS,neutral
31287.0,Advaxis shares are trading lower on higher-than-average volume. Not seeing any company-specific news to justify the price action.,2019-11-19 11:16:00-05:00,ADXS,neutral
31288.0,Advaxis shares are trading higher on above-average volume. Not seeing any company-specific news to justify the price action. NOTE: Penny stocks can have volatile price action with no catalyst.,2019-11-18 11:41:00-05:00,ADXS,neutral
31289.0,17 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-11-06 07:52:00-05:00,ADXS,neutral
31290.0,17 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-11-01 08:21:00-04:00,ADXS,neutral
31291.0,28 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-10-29 08:33:00-04:00,ADXS,neutral
31292.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-10-28 08:21:00-04:00,ADXS,neutral
31293.0,Advaxis Sees Cash Balance Extending Into 2021,2019-10-24 09:07:00-04:00,ADXS,neutral
31294.0,"Advaxis Offers Updates For ADXS-HOT, ADXS-NEO, ADXS-PSA, ADXS-HPV Clinical Programs",2019-10-24 09:07:00-04:00,ADXS,neutral
31295.0,22 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-10-15 08:04:00-04:00,ADXS,neutral
31296.0,9 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-10-14 07:54:00-04:00,ADXS,neutral
31297.0,28 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-10-11 08:42:00-04:00,ADXS,neutral
31298.0,Advaxis shares are trading lower despite no company-specific news. This could potentially be profit taking after the stocked increased approximately 10% in the last 5 days.,2019-10-10 14:26:00-04:00,ADXS,positive
31299.0,Advaxis Reports Collaboration With UCLA For Glioblastoma Immunotherapy Discovery Research,2019-10-10 08:02:00-04:00,ADXS,neutral
31300.0,50 Biggest Movers From Yesterday,2019-10-10 05:17:00-04:00,ADXS,neutral
31301.0,28 Stocks Moving In Wednesday's Mid-Day Session,2019-10-09 12:56:00-04:00,ADXS,neutral
31302.0,Advaxis shares are trading higher in sympathy with the overall market on renewed optimism in the upcoming U.S.-China trade talks.,2019-10-09 10:35:00-04:00,ADXS,positive
31303.0,13 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-09 07:54:00-04:00,ADXS,neutral
31304.0,9 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-10-08 08:10:00-04:00,ADXS,neutral
31305.0,38 Biggest Movers From Yesterday,2019-10-08 05:39:00-04:00,ADXS,neutral
31306.0,30 Stocks Moving In Monday's Mid-Day Session,2019-10-07 12:32:00-04:00,ADXS,neutral
31307.0,Advaxis shares are trading higher after the company announced an update to its prolonged survival data in the Phase 1/2 of the ADXS-PSA Trial.,2019-10-07 08:45:00-04:00,ADXS,positive
31308.0,16 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-10-07 08:09:00-04:00,ADXS,neutral
31309.0,Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial,2019-10-07 08:01:00-04:00,ADXS,neutral
31310.0,16 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-10-04 08:21:00-04:00,ADXS,neutral
31311.0,Advaxis shares are trading higher on higher-than-average volume. Not seeing any news to justify the price action.,2019-10-03 10:12:00-04:00,ADXS,positive
31312.0,23 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-10-01 08:24:00-04:00,ADXS,neutral
31313.0,21 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-09-26 08:10:00-04:00,ADXS,neutral
31314.0,"The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J",2019-09-26 07:54:00-04:00,ADXS,positive
31315.0,55 Biggest Movers From Yesterday,2019-09-26 04:34:00-04:00,ADXS,neutral
31316.0,Advaxis shares are trading higher. This could potentially be a rebound after the stock dropped approximately 30% in the past month.,2019-09-25 13:15:00-04:00,ADXS,positive
31317.0,34 Stocks Moving In Wednesday's Mid-Day Session,2019-09-25 12:02:00-04:00,ADXS,neutral
31318.0,Stocks That Hit 52-Week Lows On Wednesday,2019-09-25 11:56:00-04:00,ADXS,negative
31319.0,23 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-09-25 08:17:00-04:00,ADXS,neutral
31320.0,"The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug",2019-09-25 07:13:00-04:00,ADXS,positive
31321.0,Advaxis shares are trading lower as traders potentially took profits after the stock increased roughly 25% yesterday.,2019-09-19 15:51:00-04:00,ADXS,positive
31322.0,18 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-09-19 08:19:00-04:00,ADXS,neutral
31323.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Tuesday, September 17, 2019",2019-09-17 12:16:00-04:00,ADXS,positive
31324.0,22 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-09-16 08:29:00-04:00,ADXS,neutral
31325.0,"The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris",2019-09-10 07:36:00-04:00,ADXS,neutral
31326.0,27 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-09-09 08:42:00-04:00,ADXS,neutral
31327.0,"Advaxis Q3 EPS $(1) Beats $(1.32) Estimate, Sales $6K Down From $1.131M YoY",2019-09-09 08:10:00-04:00,ADXS,neutral
31328.0,"The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved",2019-08-28 07:31:00-04:00,ADXS,positive
31329.0,"The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO",2019-08-27 07:29:00-04:00,ADXS,positive
31330.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Mon., August 26, 2019",2019-08-26 12:51:00-04:00,ADXS,positive
31331.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Fri., August 16, 2019",2019-08-16 12:54:00-04:00,ADXS,positive
31332.0,Stocks That Hit 52-Week Lows On Friday,2019-08-16 11:44:00-04:00,ADXS,negative
31333.0,"The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results",2019-08-13 07:25:00-04:00,ADXS,neutral
31334.0,Stocks That Set New 52-Week Lows Friday Morning,2019-08-02 10:46:00-04:00,ADXS,negative
31335.0,28 Healthcare Stocks Moving In Tuesday's After-Market Session,2019-07-31 04:01:00-04:00,ADXS,neutral
31336.0,33 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-30 09:16:00-04:00,ADXS,neutral
31337.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,ADXS,positive
31338.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Mon., July 29, 2019",2019-07-29 12:24:00-04:00,ADXS,positive
31339.0,Stocks That Managed to Breach 52-Week Lows Friday,2019-07-26 15:45:00-04:00,ADXS,negative
31340.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-26 10:09:00-04:00,ADXS,neutral
31341.0,30 Healthcare Stocks Moving In Thursday's After-Market Session,2019-07-26 04:36:00-04:00,ADXS,neutral
31342.0,"The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index",2019-07-24 07:08:00-04:00,ADXS,neutral
31343.0,List of Companies Reaching Yearly Lows Tuesday,2019-07-23 14:58:00-04:00,ADXS,neutral
31344.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Tue., July 23, 2019",2019-07-23 13:52:00-04:00,ADXS,positive
31345.0,Advaxis shares are trading lower after the company priced 9.2 million shares for a common stock offering at $0.70 per share.,2019-07-23 09:48:00-04:00,ADXS,positive
31346.0,"Advaxis Prices 9.2M Share Common Stock, Warrants Offering At $0.70/Share",2019-07-23 08:34:00-04:00,ADXS,positive
31347.0,"The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation",2019-07-23 07:26:00-04:00,ADXS,negative
31348.0,Advaxis Files For Offering Of Up To 11.8M Shares Of Common Stock And Warrants To Purchase Up To 8.9M Shares Of Common Stock,2019-07-22 09:52:00-04:00,ADXS,positive
31349.0,Advaxis shares are trading higher after the company said new immune data from its ADXS-NEO Phase 1 study supports clinical potential for neoantigen-directed immunotherapies.,2019-07-15 08:13:00-04:00,ADXS,positive
31350.0,Advaxis Says New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential Shows Suppot for Neoantigen-Directed Immunotherapies,2019-07-15 08:06:00-04:00,ADXS,positive
31351.0,"The Daily Biotech Pulse: Roche Presents Positive Hemlibra Data, Amgen's Tender Offer For Nuevolution Complete, Genmab Offering",2019-07-09 07:11:00-04:00,ADXS,positive
31352.0,"The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight",2019-07-05 08:55:00-04:00,ADXS,negative
31353.0,48 Biggest Movers From Wednesday,2019-07-05 05:08:00-04:00,ADXS,neutral
31354.0,33 Stocks Moving In Wednesday's Mid-Day Session,2019-07-03 12:47:00-04:00,ADXS,neutral
31355.0,62 Biggest Movers From Yesterday,2019-06-28 05:20:00-04:00,ADXS,neutral
31356.0,48 Stocks Moving In Thursday's Mid-Day Session,2019-06-27 12:41:00-04:00,ADXS,neutral
31357.0,36 Stocks Moving In Thursday's Pre-Market Session,2019-06-27 08:12:00-04:00,ADXS,neutral
31358.0,Advaxis Sees Cash Usage Over Next 12 Months $33M-$37M Related To Redirection Of Resources To Neoantigen Programs,2019-06-27 06:56:00-04:00,ADXS,neutral
31359.0,UPDATE: Advaxis Sees $80M-$90M In Remaining Costs To Close AIM2CERV Trial,2019-06-27 06:56:00-04:00,ADXS,neutral
31360.0,"Advaxis To Increase Focus On Neoantigen-Directed Immunotherapies, Is Closing AIM2CERV Phase 3 Trial With Axalimogene Filolisbac",2019-06-27 06:55:00-04:00,ADXS,positive
31361.0,"The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale",2019-06-18 07:31:00-04:00,ADXS,neutral
31362.0,60 Biggest Movers From Yesterday,2019-06-18 04:54:00-04:00,ADXS,neutral
31363.0,44 Stocks Moving In Monday's Mid-Day Session,2019-06-17 12:23:00-04:00,ADXS,neutral
31364.0,66 Biggest Movers From Yesterday,2019-06-12 04:44:00-04:00,ADXS,neutral
31365.0,48 Stocks Moving In Tuesday's Mid-Day Session,2019-06-11 12:36:00-04:00,ADXS,neutral
31366.0,"The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering",2019-06-11 07:34:00-04:00,ADXS,positive
31367.0,"Advaxis Q2 EPS $(1.59) Misses $(1.2) Estimate, Sales $1.19M Down From $1.747M YoY",2019-06-10 16:05:00-04:00,ADXS,negative
31368.0,"Earnings Scheduled For June 10, 2019",2019-06-10 06:39:00-04:00,ADXS,neutral
31369.0,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",2019-05-31 07:34:00-04:00,ADXS,positive
31370.0,44 Stocks Moving In Wednesday's Mid-Day Session,2019-05-15 12:56:00-04:00,ADXS,neutral
31371.0,Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug,2019-05-15 10:25:00-04:00,ADXS,negative
31372.0,"Advaxis Shares Resume Trade, Up 15.7%",2019-05-15 08:31:00-04:00,ADXS,positive
31373.0,Advaxis Shares To Resume Trade At 8:30 a.m. EDT,2019-05-15 08:09:00-04:00,ADXS,positive
31374.0,UPDATE: Advaxis Says FDA Acknowledged Co. Satisfactorily Addressed All Hold Questions,2019-05-15 08:03:00-04:00,ADXS,positive
31375.0,Advaxis Reports FDA Lifted Partial Clinical Hold On AIM2CERV,2019-05-15 08:02:00-04:00,ADXS,neutral
31376.0,Advaxis Shares Halted News Pending,2019-05-15 07:55:00-04:00,ADXS,positive
31377.0,Advaxis Reports 2 Poster Presentations At Frontiers In Cancer Immunotherapy Conference,2019-05-14 09:09:00-04:00,ADXS,negative
31378.0,55 Biggest Movers From Yesterday,2019-04-04 05:19:00-04:00,ADXS,neutral
31379.0,Mid-Afternoon Market Update: Acuity Brands Gains On Earnings Beat; Advaxis Shares Plunge,2019-04-03 14:27:00-04:00,ADXS,positive
31380.0,40 Stocks Moving In Wednesday's Mid-Day Session,2019-04-03 12:41:00-04:00,ADXS,neutral
31381.0,Mid-Day Market Update: NASDAQ Up Over 1%; Obalon Therapeutics Shares Plummet,2019-04-03 12:00:00-04:00,ADXS,positive
31382.0,Advaxis 13G From Sabby Mgmt. Shows New 7.49% Stake,2019-04-03 10:50:00-04:00,ADXS,neutral
31383.0,Mid-Morning Market Update: Markets Gain; Signet Jewelers Profit Beats Estimates,2019-04-03 10:19:00-04:00,ADXS,positive
31384.0,Advaxis shares are trading lower after the company reported a 2.5 million common shares offering at $4 per share.,2019-04-03 08:39:00-04:00,ADXS,positive
31385.0,"The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings",2019-04-03 08:19:00-04:00,ADXS,positive
31386.0,30 Stocks Moving In Wednesday's Pre-Market Session,2019-04-03 08:04:00-04:00,ADXS,neutral
31387.0,Advaxis Prices 2.5M Share Common Stock Offering At $4/Share,2019-04-03 07:30:00-04:00,ADXS,positive
31388.0,54 Biggest Movers From Yesterday,2019-04-03 05:42:00-04:00,ADXS,neutral
31389.0,4 Stocks Moving In Tuesday's After-Hours Session,2019-04-02 16:59:00-04:00,ADXS,neutral
31390.0,"Advaxis Reports Offering Of Common Shares, No Size Disclosed",2019-04-02 16:05:00-04:00,ADXS,neutral
31391.0,51 Stocks Moving In Tuesday's Mid-Day Session,2019-04-02 12:27:00-04:00,ADXS,neutral
31392.0,32 Stocks Moving In Tuesday's Pre-Market Session,2019-04-02 08:20:00-04:00,ADXS,neutral
31393.0,58 Biggest Movers From Yesterday,2019-04-02 05:45:00-04:00,ADXS,neutral
31394.0,Advaxis Shares Surge After Positive Clinical Trial Updates,2019-04-01 14:27:00-04:00,ADXS,positive
31395.0,46 Stocks Moving In Monday's Mid-Day Session,2019-04-01 13:06:00-04:00,ADXS,neutral
31396.0,"Benzinga Pro's Top 8 Most-Searched Tickers For Morning Of Monday, Apr. 1, 2019",2019-04-01 09:49:00-04:00,ADXS,positive
31397.0,Advaxis shares are trading higher after the company announced updated data for its Phase 1/2 KEYNOTE-046 study to prolong survival in metastatic prostate cancer.,2019-04-01 08:28:00-04:00,ADXS,negative
31398.0,24 Stocks Moving In Monday's Pre-Market Session,2019-04-01 08:14:00-04:00,ADXS,neutral
31399.0,Advaxis Says its Phase 1/2 KEYNOTE-046 Study Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer,2019-04-01 08:04:00-04:00,ADXS,negative
31400.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,ADXS,neutral
31401.0,Advaxis Highlights Presentation Of ADXS-NEO Data In Poster 'Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients' At AACR meeting,2019-03-29 15:01:00-04:00,ADXS,negative
31402.0,"Advaxis Reports Board Approved 1-For-15 Reverse Stock Split, Effective Mar. 29, 2019",2019-03-28 13:00:00-04:00,ADXS,positive
31403.0,52 Biggest Movers From Yesterday,2019-03-26 05:04:00-04:00,ADXS,neutral
31404.0,41 Stocks Moving In Monday's Mid-Day Session,2019-03-25 12:51:00-04:00,ADXS,neutral
31405.0,Advaxis shares are trading higher after the company was granted a US patent related to Axalimogene Filolisbac.,2019-03-25 08:40:00-04:00,ADXS,positive
31406.0,Advaxis Granted a US Patent Related to Axalimogene Filolisbac,2019-03-25 08:07:00-04:00,ADXS,positive
31407.0,Advaxis shares are trading higher after the company reported better-than-expected Q1 results.,2019-03-13 11:39:00-04:00,ADXS,positive
31408.0,Advaxis shares are trading higher after the company reported higher-than-expected Q1 earnings.,2019-03-12 08:41:00-04:00,ADXS,positive
31409.0,"Advaxis Q1 EPS $0.18 May not Compare To $(0.25) Estimate, Sales $19.69M May Not Compare To $1M Estimate",2019-03-12 08:01:00-04:00,ADXS,neutral
31410.0,Advaxis Announces Presentations Of ADXS-NEO And ADXS-PSA Data At Upcoming American Association For Cancer Research Annual Meeting,2019-03-11 08:05:00-04:00,ADXS,negative
31411.0,Advaxis Announces Enrollment Of First Patient In Phase 1/2 Trial For ADXS-HOT In Treatment Of Non-Small Cell Lung Cancer,2019-02-14 08:37:00-05:00,ADXS,negative
31412.0,Advaxis Highlights 2 Presentations Which Highlighted Potential Of Co. Vectors To Generate T-Cell Responses,2019-01-25 08:07:00-05:00,ADXS,neutral
31413.0,"The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial",2019-01-24 07:45:00-05:00,ADXS,negative
31414.0,Advaxis shares are trading lower after the company reported the Phase 3 AIM2CERV study was put on partial clinical hold.,2019-01-23 16:54:00-05:00,ADXS,neutral
31415.0,"Advaxis Shares Resume Trade, Down 11.5%",2019-01-23 16:36:00-05:00,ADXS,positive
31416.0,Advaxis Shares To Resume Trade At 4:35 p.m. EST,2019-01-23 16:23:00-05:00,ADXS,positive
31417.0,UPDATE: Advaxis Says Enrolled Patients In AIM2CERV Study Continue To Be Treated,2019-01-23 16:10:00-05:00,ADXS,neutral
31418.0,"Advaxis Reports Phase 3 AIM2CERV Study Place On Partial Clinical Hold, Cites CMC Requests",2019-01-23 16:10:00-05:00,ADXS,neutral
31419.0,Advaxis Shares Halted News Pending,2019-01-23 16:09:00-05:00,ADXS,positive
31420.0,"The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA",2019-01-11 08:38:00-05:00,ADXS,negative
31421.0,Advaxis FY18 EPS $(1.29) vs $(2.31) In Same Qtr. Last Year,2019-01-10 16:07:00-05:00,ADXS,neutral
31422.0,"The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits",2019-01-10 08:27:00-05:00,ADXS,negative
31423.0,When Larger Firms Walk Away From Partnerships With Smaller Ones: How Bad Is The Damage?,2018-12-21 13:38:00-05:00,ADXS,negative
31424.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,ADXS,negative
31425.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,ADXS,negative
31426.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,ADXS,positive
31427.0,H.C. Wainwright Downgrades Advaxis to Neutral,2018-12-18 08:56:00-05:00,ADXS,neutral
31428.0,"Advaxis shares are trading 37% lower after the company received a written notice of termination from Amgen for the license and collaboration Agreement for ADXS-NEO effective February 8, 2019.",2018-12-14 12:21:00-05:00,ADXS,positive
31429.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018",2018-12-14 11:03:00-05:00,ADXS,negative
31430.0,"Advaxis shares down 25% following news the company received written notice from Amgen related to termination of its license, collaboration deal for ADXS-NEO program",2018-12-13 17:42:00-05:00,ADXS,positive
31431.0,Advaxis Announces It Has Received Written Notice Of Termination From Amgen With Regards To License And Collaboration Agreement Of ADXS-NEO Program,2018-12-13 16:39:00-05:00,ADXS,positive
31432.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,ADXS,neutral
31433.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,ADXS,negative
31434.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,ADXS,negative
31435.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018",2018-11-23 09:09:00-05:00,ADXS,negative
31436.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018",2018-11-21 08:50:00-05:00,ADXS,negative
31437.0,"Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018",2018-11-19 10:16:00-05:00,ADXS,negative
31438.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Nov. 16, 2018",2018-11-16 10:37:00-05:00,ADXS,negative
31439.0,"The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal",2018-11-16 08:08:00-05:00,ADXS,positive
31440.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018",2018-11-15 11:37:00-05:00,ADXS,negative
31441.0,"Advaxis Says Is Continuing Its Phase 3 AIM2CERV Study; Sees Data On ADXS-PSA, ADXS-NEO, ADXS-HOT In 2019",2018-11-02 08:03:00-04:00,ADXS,neutral
31442.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,ADXS,negative
31443.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,ADXS,negative
31444.0,"The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering",2018-10-24 07:48:00-04:00,ADXS,positive
31445.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,ADXS,negative
31446.0,"The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",2018-10-23 08:35:00-04:00,ADXS,positive
31447.0,"The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs",2018-10-18 07:56:00-04:00,ADXS,positive
31448.0,"The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise",2018-10-17 08:15:00-04:00,ADXS,negative
31449.0,"Stocks Which Set New 52-Week Low Yesterday, October 11th",2018-10-12 11:30:00-04:00,ADXS,negative
31450.0,"Stocks Which Set New 52-Week Low Yesterday, September 13th",2018-09-14 09:30:00-04:00,ADXS,negative
31451.0,"The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut",2018-09-14 08:38:00-04:00,ADXS,neutral
31452.0,"Stocks Which Set New 52-Week Low Yesterday, September 12th",2018-09-13 10:19:00-04:00,ADXS,negative
31453.0,"The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx",2018-09-13 08:42:00-04:00,ADXS,neutral
31454.0,"Stocks Which Set New 52-Week Low Yesterday, September 11th",2018-09-12 15:29:00-04:00,ADXS,negative
31455.0,"The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt",2018-09-12 08:26:00-04:00,ADXS,positive
31456.0,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",2018-09-11 08:25:00-04:00,ADXS,negative
31457.0,"Stocks Which Set New 52-Week Low Friday, September 7th",2018-09-10 16:38:00-04:00,ADXS,negative
31458.0,"Advaxis Q3 EPS $(0.27) Misses $(0.25) Estimate, Sales $1.13M Miss $1.85M Estimate",2018-09-10 16:30:00-04:00,ADXS,negative
31459.0,52 Biggest Movers From Friday,2018-09-10 05:21:00-04:00,ADXS,neutral
31460.0,Mid-Afternoon Market Update: Okta Gains After Strong Q2 Results; eGain Shares Plummet,2018-09-07 14:54:00-04:00,ADXS,positive
31461.0,44 Stocks Moving In Friday's Mid-Day Session,2018-09-07 12:54:00-04:00,ADXS,neutral
31462.0,Mid-Day Market Update: Dow Falls 150 Points; Dicerna Pharmaceuticals Shares Spike Higher,2018-09-07 12:30:00-04:00,ADXS,positive
31463.0,Advaxis shares are down 29.7% after the company priced a mixed offering for an aggregate amount of $20 million.,2018-09-07 10:19:00-04:00,ADXS,positive
31464.0,"Advaxis Prices Mixed Offering of 16,666,666 Shares Common Stock and 14,166,666 Warrants at an Aggregate Amount of $20M",2018-09-07 09:26:00-04:00,ADXS,positive
31465.0,"The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering",2018-09-07 07:55:00-04:00,ADXS,neutral
31467.0,Advaxis Licenses ADXS-HER2 To OS Therapies for Evaluation In Treatment Of Osteosarcoma,2018-09-04 08:11:00-04:00,ADXS,neutral
31468.0,44 Biggest Movers From Friday,2018-08-27 04:34:00-04:00,ADXS,neutral
31469.0,40 Stocks Moving In Friday's Mid-Day Session,2018-08-24 12:47:00-04:00,ADXS,neutral
31470.0,30 Stocks Moving In Friday's Pre-Market Session,2018-08-24 08:08:00-04:00,ADXS,neutral
31471.0,Advaxis S-3 Shows Registration For $250M Mixed Securities Shelf Offering,2018-08-23 17:34:00-04:00,ADXS,positive
31472.0,Advaxis Shares Up 8% AFter Co. Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for Non-Small Cell Lung Cancer,2018-07-30 09:38:00-04:00,ADXS,negative
31473.0,Adaxis Announces FDA Allowance of IND Application for ADXS-HOTDrug Candidate,2018-07-30 08:01:00-04:00,ADXS,neutral
31474.0,38 Biggest Movers From Friday,2018-07-16 04:47:00-04:00,ADXS,neutral
31475.0,30 Stocks Moving In Friday's Mid-Day Session,2018-07-13 12:38:00-04:00,ADXS,neutral
31476.0,Advaxis Shares Soar After FDA Lifts Clinical Hold On Cancer Drug,2018-07-13 11:37:00-04:00,ADXS,negative
31477.0,Advaxis Shares Up 40.2% Premarket After FDA Lifted Clinical Hold On Co.'s Investigational New Drug Axalimogene Filolisbic (AXAL); Hold Was Issued March 9 After Co. Submitted Safety Report to FDA Regarding Patient Death In Individual Treated With AXAL,2018-07-13 08:45:00-04:00,ADXS,neutral
31478.0,"Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering",2018-07-13 08:34:00-04:00,ADXS,neutral
31479.0,Advaxis Announces FDA Lifts Clinical Hold On Phase 1/2 Combination Study Of Axalimogene Filolisbac With Durvalumab,2018-07-13 08:02:00-04:00,ADXS,neutral
31480.0,"Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial",2018-07-12 08:37:00-04:00,ADXS,neutral
31481.0,UPDATE: Advaxis Reports Selection Of Prostate Cancer As Second Cancer Type Within Its ADXS-HOT Program,2018-07-10 08:03:00-04:00,ADXS,negative
31482.0,Advaxis Reports Plan To Withdraw Conditional Marketing Authorization Application In EU For Axalimogene Filolisbac To Treat Metastatic Cervical Cancer,2018-07-10 08:02:00-04:00,ADXS,negative
31483.0,"Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos",2018-06-29 08:11:00-04:00,ADXS,positive
31484.0,38 Biggest Movers From Yesterday,2018-06-14 04:17:00-04:00,ADXS,neutral
31485.0,31 Stocks Moving In Wednesday's Mid-Day Session,2018-06-13 12:22:00-04:00,ADXS,neutral
31486.0,10 Biggest Price Target Changes For Wednesday,2018-06-13 09:49:00-04:00,ADXS,neutral
31487.0,"Benzinga's Top Upgrades, Downgrades For June 13, 2018",2018-06-13 09:19:00-04:00,ADXS,positive
31488.0,"Jefferies Downgrades Advaxis to Hold, Lowers Price Target to $2",2018-06-13 07:39:00-04:00,ADXS,negative
31489.0,Advaxis Reports Dosing Of First Patient With ADXS-NEO,2018-06-11 08:03:00-04:00,ADXS,neutral
31490.0,45 Biggest Movers From Yesterday,2018-06-08 04:07:00-04:00,ADXS,neutral
31491.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-06-07 12:30:00-04:00,ADXS,neutral
31492.0,Advaxis Q2 EPS $(0.27) Beats $(0.46) Estimate,2018-06-07 09:07:00-04:00,ADXS,neutral
31493.0,"Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study",2018-06-07 07:58:00-04:00,ADXS,neutral
31494.0,"Earnings Scheduled For June 7, 2018",2018-06-07 04:15:00-04:00,ADXS,neutral
31495.0,Advaxis Names Molly Henderson CFO,2018-06-06 08:04:00-04:00,ADXS,neutral
31496.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,ADXS,negative
31497.0,Advaxis Highlights 2 Studies On ADXS-NEO As Anti-Cancer Immunotherapy Agent Presented At AACR Annual Meeting,2018-05-11 08:05:00-04:00,ADXS,neutral
31498.0,5 Biggest Price Target Changes For Wednesday,2018-03-14 09:52:00-04:00,ADXS,neutral
31499.0,"H.C. Wainwright Maintains Buy on Advaxis, Lowers Price Target to $6.00",2018-03-14 07:34:00-04:00,ADXS,negative
31500.0,45 Biggest Movers From Yesterday,2018-03-14 04:55:00-04:00,ADXS,neutral
31501.0,Mid-Afternoon Market Update: Commercial Vehicle Group Falls Following Q4 Results; Bovie Medical Shares Surge,2018-03-13 14:30:00-04:00,ADXS,positive
31502.0,Advaxis Shares Down 16.3% After Co. Announced Monday a Clinical Hold In Axalimogene Filolisbac Phase 1/2 Combination Study With AstraZeneca's IMFINZI,2018-03-13 13:51:00-04:00,ADXS,positive
31503.0,35 Stocks Moving In Tuesday's Mid-Day Session,2018-03-13 12:28:00-04:00,ADXS,neutral
31504.0,Mid-Day Market Update: Crude Oil Down 1.5%; Proteostasis Therapeutics Shares Spike Higher,2018-03-13 12:10:00-04:00,ADXS,negative
31505.0,Advaxis Reports Q1 EPS $(0.49) vs $(0.55) Est.,2018-03-12 16:15:00-04:00,ADXS,neutral
31506.0,UPDATE: Advaxis Conf. Call To Be Held At 4:30 p.m. ET,2018-03-12 16:14:00-04:00,ADXS,neutral
31507.0,Advaxis Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca's IMFINZI,2018-03-12 16:14:00-04:00,ADXS,neutral
31508.0,56 Biggest Movers From Yesterday,2018-02-23 05:17:00-05:00,ADXS,neutral
31509.0,Mid-Afternoon Market Update: Crude Oil Up Over 1.5%; Whiting Petroleum Shares Climb After Strong Q4 Results,2018-02-22 14:30:00-05:00,ADXS,positive
31510.0,Advaxis Shares Down 25% After Co. Priced 10M Share Offering At $2/Share,2018-02-22 12:40:00-05:00,ADXS,positive
31511.0,45 Stocks Moving In Thursday's Mid-Day Session,2018-02-22 12:26:00-05:00,ADXS,neutral
31512.0,Mid-Day Market Update: Dow Rises Over 1%; Applied Optoelectronics Shares Plummet,2018-02-22 12:05:00-05:00,ADXS,positive
31513.0,Mid-Morning Market Update: Markets Open Higher; PPL Profit Tops Expectations,2018-02-22 10:13:00-05:00,ADXS,positive
31514.0,Advaxis Prices 10M Share Offering At $2/Share,2018-02-22 09:15:00-05:00,ADXS,positive
31515.0,30 Stocks Moving In Thursday's Pre-Market Session,2018-02-22 07:54:00-05:00,ADXS,neutral
31516.0,"Advaxis Announces Common Stock Offering, No Size Disclosed",2018-02-21 16:45:00-05:00,ADXS,negative
31517.0,Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac,2018-02-13 08:32:00-05:00,ADXS,neutral
31518.0,Advaxis Reports Publication Of Phase 2 Results On Axalimogene Filolisbac For Treatment Of Recurrent Metastatic Cervical Cancer: Showed Treatment 'resulted in an overall 12-month survival rate of ~35%',2018-02-12 09:15:00-05:00,ADXS,negative
31519.0,32 Stocks Moving In Tuesday's Pre-Market Session,2017-12-26 08:12:00-05:00,ADXS,neutral
31520.0,38 Biggest Movers From Yesterday,2017-12-22 05:50:00-05:00,ADXS,neutral
31521.0,36 Stocks Moving In Thursday's Mid-Day Session,2017-12-21 12:17:00-05:00,ADXS,neutral
31522.0,35 Stocks Moving In Thursday's Pre-Market Session,2017-12-21 08:00:00-05:00,ADXS,neutral
31523.0,Advaxis Reports Q4 EPS $(2.31) vs. $(2.08) In Same Qtr. Last Year,2017-12-20 16:17:00-05:00,ADXS,neutral
31524.0,Aratana Therapeutics Reports Granted Conditional License For Canine Osteosarcoma Therapeutic,2017-12-20 08:09:00-05:00,ADXS,positive
31525.0,"Earnings Scheduled For December 20, 2017",2017-12-20 04:12:00-05:00,ADXS,neutral
31526.0,32 Stocks Moving In Monday's Pre-Market Session,2017-11-27 08:03:00-05:00,ADXS,neutral
31527.0,Advaxis to Receive $4.5M through the New Jersey Economic Development Authority NOL Program,2017-11-01 08:08:00-04:00,ADXS,positive
31528.0,18 Stocks Moving In Tuesday's Pre-Market Session,2017-10-03 08:51:00-04:00,ADXS,neutral
31529.0,8-K From Advaxis Shows Registrational Study Of ADXS-DUAL In Metastatic Cervical Cancer In Combo With Opdivo To Begin In 1H'18,2017-09-25 17:08:00-04:00,ADXS,negative
31530.0,"Cantor Fitzgerald Global Healthcare Conference Begins Today, Presenters Include: Verastem, Advaxis, Exelixis, Heron Therapeutics, and Enanta Pharma",2017-09-25 09:30:00-04:00,ADXS,neutral
31531.0,Mid-Afternoon Market Update: Sage Therapeutics Drops After Brexanolone Drug Fails Phase III Testing; Aldeyra Therapeutics Shares Gain,2017-09-12 14:41:00-04:00,ADXS,positive
31532.0,10 Biggest Mid-Day Losers For Thursday,2017-09-12 13:08:00-04:00,ADXS,negative
31533.0,Mid-Day Market Update: Advaxis Drops Following Q3 Results; Aethlon Medical Shares Climb,2017-09-12 12:04:00-04:00,ADXS,positive
31534.0,Mid-Morning Market Update: Markets Open Higher; Progress Software Reports Strong Preliminary Results,2017-09-12 10:05:00-04:00,ADXS,positive
31535.0,"Advaxis Reports Q3 Cash, Cash Equivalents, Investments $89.4M, $34.2M In Disbursements, Cash Receivables $8.2M, Net Loss $1.74/Share",2017-09-11 16:01:00-04:00,ADXS,negative
31536.0,15 Biggest Mid-Day Losers For Friday,2017-07-07 12:59:00-04:00,ADXS,negative
31537.0,"Stocks To Watch For July 7, 2017",2017-07-07 04:32:00-04:00,ADXS,neutral
31538.0,Advaxis Shares To Resume Trade At 5 p.m. EDT,2017-07-06 16:39:00-04:00,ADXS,positive
31539.0,Advaxis Reports Resignation Of CEO Daniel O'Connor; Anthony Lombardo Named As Interim CEO,2017-07-06 16:30:00-04:00,ADXS,negative
31540.0,Advaxis Halted News Pending,2017-07-06 16:27:00-04:00,ADXS,neutral
31541.0,Advaxis Confirms is on Track to Initiate Clinical Studies of ADXS-NEO Later this Year,2017-06-13 12:34:00-04:00,ADXS,neutral
31542.0,Advaxis Confirms Company Is On Track To Start Clinical Studies of ADXS-NEO Later This Year,2017-06-13 12:34:00-04:00,ADXS,neutral
31543.0,Companies Holding Analyst/Investor Days Today Include Novo-Nordisk and Advaxis,2017-06-12 08:32:00-04:00,ADXS,neutral
31544.0,"Advaxis, Synthetic Genomics Report Launch of cGMP Suite for Pharma Quality Manufacturing of Synthetic DNA for Co. Trials",2017-06-01 08:02:00-04:00,ADXS,neutral
31545.0,Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo,2017-05-30 07:01:00-04:00,ADXS,neutral
31546.0,"Advaxis Offers Phase 1 Data of Higher Dose Axalimogene Filolisbac: 9 Patients Enrolled, 1 Instance of Dose-Limiting Toxicity",2017-05-15 09:08:00-04:00,ADXS,neutral
31547.0,Advaxis Announces EMA Issues Advanced Therapy Medicinal Product Certifacte For MAA Submission For Axalimogene Filolisbac,2017-03-23 08:03:00-04:00,ADXS,positive
31548.0,15 Biggest Mid-Day Gainers For Monday,2017-03-06 12:56:00-05:00,ADXS,neutral
31549.0,20 Stocks Moving In Monday's Pre-Market Session,2017-03-06 08:10:00-05:00,ADXS,neutral
31550.0,Advaxis Says Planning to Initiate Phase 1 Trial in 2017,2017-03-06 06:03:00-05:00,ADXS,neutral
31551.0,Advaxis Gets FDA Acceptance of IND for ADXS-NEO,2017-03-06 06:03:00-05:00,ADXS,positive
31552.0,UPDATE: Advaxis To Receive Future Payments Of Up To $358M From SELLAS If Certain Milestones Are MEt,2017-02-27 08:06:00-05:00,ADXS,positive
31553.0,"Advaxis, SELLAS Reports Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy",2017-02-27 08:01:00-05:00,ADXS,positive
31554.0,Advaxis Reports Abstract on Phase 2 GOG-0265 Trial Evaluating Axalimogene Filolisbac for Metastatic Cervical Cancer Accepted as Late-Breaking Presentation at SGO in March,2017-01-30 08:37:00-05:00,ADXS,negative
31555.0,Advaxis Reports GOG-0265 12-Mo. Overall Survival Rate in Stage 2 37.5%,2016-10-24 08:08:00-04:00,ADXS,neutral
31556.0,"Advaxis Initiates Combination Portion of Phase 1/2 Study with Merck, Study To Evaluate KEYTRUDA In Combination With ADXS-PSA",2016-10-20 07:37:00-04:00,ADXS,neutral
31557.0,Advaxis to Receive $2.5M through the New Jersey Economic Development Authority NOL Program,2016-10-13 08:00:00-04:00,ADXS,positive
31558.0,12 Biggest Mid-Day Gainers For Tuesday,2016-10-04 12:28:00-04:00,ADXS,neutral
31559.0,Advaxis Names Christopher Duke as COO,2016-10-03 08:02:00-04:00,ADXS,neutral
31560.0,Advaxis Says Believes Current Cash Position is Sufficient to Fund its Business Plan Approximately through Q2 of FY 2019 -10Q,2016-09-08 06:13:00-04:00,ADXS,positive
31561.0,"Advaxis Qtr EPS ($0.48) vs ($0.18) est, No Revenue",2016-09-08 06:10:00-04:00,ADXS,negative
31562.0,Advaxis Sells off to Low of $13.90 on Volume,2016-08-16 13:15:00-04:00,ADXS,negative
31563.0,Advaxis Announces Securing $30M Direct Placement Financing to Healthcare Specialist Investors,2016-08-16 09:33:00-04:00,ADXS,positive
31564.0,"Advaxis Meets Stage 1 Primary Objective, Demonstrates Increased Systemic HPV-Reactive T-Cell Responses",2016-08-11 08:07:00-04:00,ADXS,positive
31565.0,Advaxis Announces Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage,2016-08-11 08:03:00-04:00,ADXS,negative
31566.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; RetailMeNot Shares Gain On Strong Results,2016-08-02 14:31:00-04:00,ADXS,positive
31567.0,18 Biggest Mid-Day Gainers For Tuesday,2016-08-02 12:42:00-04:00,ADXS,neutral
31568.0,Mid-Day Market Update: Dow Drops Over 100 Points; Avon Shares Surge Following Earnings Beat,2016-08-02 12:14:00-04:00,ADXS,positive
31569.0,Benzinga's Volume Movers,2016-08-02 10:34:00-04:00,ADXS,neutral
31570.0,Mid-Morning Market Update: Markets Open Lower; Pfizer Tops Q2 Views,2016-08-02 09:58:00-04:00,ADXS,positive
31571.0,Collaboration Deal With Amgen Sends Advaxis Up 30%,2016-08-02 09:12:00-04:00,ADXS,neutral
31572.0,Amgen Reports 8.9% Passive Stake in Advaxis in 13G,2016-08-02 09:11:00-04:00,ADXS,positive
31573.0,"Advaxis Shares Resume Trade, Now Up 34%",2016-08-02 08:32:00-04:00,ADXS,positive
31574.0,Advaxis Shares to Resume Trade at 8:30 a.m. EDT,2016-08-02 08:09:00-04:00,ADXS,positive
31575.0,Advaxis to Resume Trading at 8:30 AM ET,2016-08-02 08:09:00-04:00,ADXS,neutral
31576.0,"UPDATE: Amgen to Receive Exclusive Global Rights to Develop, Commercialize ADXS-NEO for Upfront Payment of $40M, Plus $25M in ADXS Shares; Milestone Payments Could Total Up to $475M",2016-08-02 08:02:00-04:00,ADXS,positive
31577.0,"Amgen, Advaxis Report Global Cancer Immunotherapies Collaboration",2016-08-02 08:01:00-04:00,ADXS,negative
31578.0,Advaxis Shares Halted News Pending,2016-08-02 07:59:00-04:00,ADXS,positive
31579.0,Advaxis Reports AXAL Receives Fast Track Designation by FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients,2016-07-21 07:13:00-04:00,ADXS,negative
31580.0,Advaxis Announces AXAL Classified As An ATMP For Treatment Of Cervical Cancer,2016-07-18 07:31:00-04:00,ADXS,negative
31581.0,Advaxis Reports FDA Granted SPA to Co.'s Phase 3 Study of AXAL in Patients with Cervical Cancer,2016-07-06 07:01:00-04:00,ADXS,negative
31582.0,Advaxis Reports First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer,2016-06-08 08:05:00-04:00,ADXS,negative
31583.0,Advaxis Announces Updated Phase 2 Data,2016-06-06 07:04:00-04:00,ADXS,neutral
31584.0,12 Stocks Moving In Thursday's Pre-Market Session,2016-04-28 08:21:00-04:00,ADXS,neutral
31585.0,Advaxis Says FDA Grants Fast Track Designation For ADXS-HER 2,2016-04-28 08:01:00-04:00,ADXS,positive
31586.0,Advaxis Reports FDA Granted Fast Track Designation for ADXS-HER2,2016-04-28 07:06:00-04:00,ADXS,positive
31587.0,"Advaxis, Merck Combination Trial Evaluating ADXS-PSA Launches Third Dose-Escalation Cohort",2016-04-05 08:01:00-04:00,ADXS,neutral
31588.0,Advaxis Combination Trial With MedImmune Commences 2nd Dose-Escalation Cohort,2016-03-29 07:07:00-04:00,ADXS,neutral
31589.0,"Advaxis HER2 Clinical Program Shows Reduction In Metastatic Disease And Increased Survival, Survival vs. Control Group 533 Days Longer With P=0.014",2016-03-21 07:08:00-04:00,ADXS,positive
31590.0,"Advaxis, Synthetic Genomics Subsidiary  SGI-DNA AnnounceFive-year Exclusive Supply Agreement",2016-03-09 07:10:00-05:00,ADXS,positive
31591.0,Advaxis Reports Dosing Has Begun in High dose Expansion Cohort in Phase 2 Study of Axalimogene Filolisbac in Patients with Recurrent Cervical Cancer,2016-03-07 07:13:00-05:00,ADXS,negative
31592.0,Advaxis Spikes to High of $8.32 on Heavy Volume,2016-03-04 11:02:00-05:00,ADXS,neutral
31593.0,Advaxis to Discuss Soon to be Launched Phase 3 Trial for Axalimogene Filolisbac at ROTH Capital Partners Conference on March 15,2016-03-04 09:08:00-05:00,ADXS,positive
31594.0,"Barclays Maintains Overweight on Advaxis, Lowers PT to $15.00",2016-02-24 05:26:00-05:00,ADXS,negative
31595.0,"Advaxis Axalimogene Filolisbac To Be Developed, Commercialized By Stendhal In Latin America, Stendhal To Pay $10M For Expenses Of AIM2CERV",2016-02-03 08:09:00-05:00,ADXS,negative
31596.0,UPDATE: Advaxis Reports Phase 3 AIM2CERV Trial to Begin in Mid '16,2016-01-08 07:09:00-05:00,ADXS,neutral
31597.0,"UPDATE: Advaxis Reports 11 Trials Evaluating LM Technology Advance to Hit Multiple Development Milestones, PD-1, PD-L! Checkpoint Combo Advanced to Second Phases of Evaluation",2016-01-08 07:09:00-05:00,ADXS,positive
31598.0,Advaxis Issues FY16 Business Outlook,2016-01-08 07:08:00-05:00,ADXS,neutral
31599.0,Why Shares Of Advaxis Moved Higher On Tuesday,2016-01-05 13:51:00-05:00,ADXS,positive
31600.0,"Advaxis Reports Establishment of Scientific Advisory Board, Includes Antoni Robas, Jedd Wolchok, Nancy Freitag, Marc Lecuit",2016-01-05 09:17:00-05:00,ADXS,neutral
31601.0,Benzinga's Volume Movers,2015-12-16 10:24:00-05:00,ADXS,neutral
31602.0,Advaxis Announces FDA Has Lifted Clinical Hold,2015-12-16 09:06:00-05:00,ADXS,neutral
31603.0,Advaxis Reports Received Orphan Drug Designation in EU for Axalimogene Filolisbac for Treatment of Anal Cancer,2015-12-14 09:07:00-05:00,ADXS,negative
31604.0,Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma,2015-12-01 09:06:00-05:00,ADXS,neutral
31605.0,Option Alert: $ADXS Jan $12.5 Put; 5600 Contracts @$2.40; Ref $12.87,2015-11-16 14:18:00-05:00,ADXS,positive
31606.0,Advaxis Spikes to High,2015-10-27 12:02:00-04:00,ADXS,neutral
31607.0,Advaxis Launches MINE Collaboration,2015-10-27 09:04:00-04:00,ADXS,neutral
31608.0,Shares of Advaxis Tumble 22+% Following Resumption of Trade,2015-10-06 16:54:00-04:00,ADXS,positive
31609.0,Shares of Advaxis to Resume Trade at 4:30 p.m. EDT,2015-10-06 16:08:00-04:00,ADXS,positive
31610.0,UPDATE: Advaxis Says Clinical Hold Relates to Single Event of One Patient with End-Stage Cervical Cancer,2015-10-06 16:03:00-04:00,ADXS,negative
31611.0,UPDATE: Advaxis Expects Clinical Hold Will Be Resolved Without Interruption To HPV Clinical Development Program,2015-10-06 16:02:00-04:00,ADXS,positive
31612.0,Advaxis Announces Clinical Hold of Axalimogene Filolisbac,2015-10-06 16:02:00-04:00,ADXS,neutral
31613.0,Advaxis Shares Halted News Pending,2015-10-06 16:01:00-04:00,ADXS,positive
31614.0,First Human Patient Treated in Phase 1b Study of Advaxis's ADXS-HER2 in HER2 Expressing Solid Tumors,2015-09-28 09:05:00-04:00,ADXS,positive
31615.0,"Barclays Initiates Coverage on Advaxis at Overweight, Announces $40.00 PT",2015-09-22 04:29:00-04:00,ADXS,negative
31616.0,Advaxis Spikes to High Following Selloff on ADXS-HPV Report,2015-09-17 14:50:00-04:00,ADXS,neutral
31617.0,"Advaxis Halted On Circuit Breaker, Swings negative now Down ~7%",2015-09-17 14:27:00-04:00,ADXS,negative
31618.0,Advaxis Reports ADXS-HPV Showed 38.5% 12-Mo. Survival in Patients with Persistent/Recurrent Metastatic Cervical Cancer,2015-09-17 14:18:00-04:00,ADXS,negative
31619.0,Advaxis Up 2.5% To $16.93 Premarket,2015-09-14 09:07:00-04:00,ADXS,neutral
31620.0,UPDATE: Advaxis Grant for ADXS-HPV Totals $1.1M Over Three Years to Baylor College of Medicine,2015-09-14 09:07:00-04:00,ADXS,positive
31621.0,Advaxis Shares Spike Higher Following FDA Phase 2 Grant News,2015-09-14 09:06:00-04:00,ADXS,positive
31622.0,"Advaxis Announces FDA Has Granted Phase 2 Study of Axalimogene Filolisbac in HPV-Associated Head, Neck Cancer",2015-09-14 09:06:00-04:00,ADXS,negative
31623.0,Phase 2 Study of Advaxis's Axalimogene Filolisbac (ADXS-HPV) in Cervical Cancer to be Presented at 2015 AGOS Annual Meeting,2015-08-31 09:05:00-04:00,ADXS,negative
31624.0,"Advaxis, Knight Therapeutics Reports Licensing Agreement",2015-08-26 08:04:00-04:00,ADXS,positive
31625.0,"Advaxis Reports Licensing Deal with Knight Therapeutics, Raises $25M Through Direct Investments from Knight",2015-08-26 08:00:00-04:00,ADXS,neutral
31626.0,Advaxis and MedImmune Commence Enrollment in Phase I/II Study of Axalimogene Filolisbac in Combination With Durvalumab for the Treatment of HPV-Associated Cancers,2015-08-20 09:05:00-04:00,ADXS,neutral
31627.0,"Christian Leone, Kevin Kotler Up Bets On Two Small-Caps",2015-08-12 19:26:00-04:00,ADXS,neutral
31628.0,13G Filing from Broadfin Capital on Advaxis Shows New 5.27% Stake,2015-08-12 15:33:00-04:00,ADXS,neutral
31629.0,"Advaxis Offers '15 Half-Year Review, Outlook",2015-06-25 07:31:00-04:00,ADXS,neutral
31630.0,Advaxis Submits Special Protocol Assessment Request to FDA for ADXS-HPV Phase 3 Clinical Trial in Cervical Cancer,2015-06-15 09:05:00-04:00,ADXS,negative
31631.0,US Stock Futures Edge Lower; Sears Q1 Loss Narrows,2015-06-08 07:45:00-04:00,ADXS,negative
31632.0,Advaxis's Cancer Immunotherapy Delays Progression of HER2+ Canine Osteosarcoma,2015-06-08 07:32:00-04:00,ADXS,negative
31633.0,Advaxis Reports FDA Clearance of Investigational New Drug Application for Phase 2 Study of ADXS-HPV and Incyte's epacadostat for the Treatment of HPV-Associated  Cervical Cancer,2015-06-01 07:31:00-04:00,ADXS,negative
31634.0,"Advaxis, Sorrento Report Formation of Collaboration to Evaluate Combo of Advaxis's Lm-LLO Immunotherapy Tech, Sorrento's Immunomodulatory Antibodies",2015-05-19 07:37:00-04:00,ADXS,neutral
31635.0,"Advaxis, Sorrento Partner to Evaluate Combinations of Advaxis's Lm-LLO Immunotherapy Technology and Sorrento's Immunomodulatory Antibodies",2015-05-19 07:32:00-04:00,ADXS,neutral
31636.0,"Advaxis, Sorrento Announces Collaboration",2015-05-19 07:32:00-04:00,ADXS,neutral
31637.0,Benzinga's Top Initiations,2015-05-15 09:47:00-04:00,ADXS,positive
31638.0,Janney Capital Initiates Advaxis At Buy,2015-05-15 08:15:00-04:00,ADXS,neutral
31639.0,"Jefferies Initiates Coverage on Advaxis at Buy, Announces $27.00 PT",2015-05-15 06:43:00-04:00,ADXS,neutral
31640.0,"Janney Capital Initiates Coverage on Advaxis at Buy, Announces $26.00 PT",2015-05-15 06:17:00-04:00,ADXS,neutral
31641.0,"MLV & Co Initiates Coverage on Advaxis at Buy, Announces $34.00 PT",2015-05-14 07:10:00-04:00,ADXS,neutral
31642.0,Advaxis Prices 2.8M Shares at $19/Share,2015-04-30 09:18:00-04:00,ADXS,positive
31643.0,Advaxis Reports Proposed Offering of Common Shares,2015-04-29 16:45:00-04:00,ADXS,positive
31644.0,Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015,2015-04-27 09:03:00-04:00,ADXS,negative
31645.0,Advaxis Presents Lm-LLO Cancer Immunotherapy Data at the 2015 American Association for Cancer Research Meeting,2015-04-21 13:11:00-04:00,ADXS,negative
31646.0,UPDATE: Advaxis Shares Fall ~2.5% Premarket Following Filing Friday of Up to $200M Stock Shelf,2015-04-20 09:29:00-04:00,ADXS,positive
31647.0,Adam Feuerstein @adamfeuerstein . @BioRunUp Tweet: $ADXS move higher is reaction to this week's $ADRO IPO. Valuation gap.,2015-04-13 11:39:00-04:00,ADXS,neutral
31648.0,"Advaxis, Merck Report Initiation of Enrollment in Phase 1/2 Study of ADXS-PSA in Combo with Anti-PD-1 Therapy",2015-04-08 07:33:00-04:00,ADXS,neutral
31649.0,"Advaxis, RTOG Foundation To Partner on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer",2015-04-06 07:30:00-04:00,ADXS,negative
31650.0,Advaxis Shares Rise 13% Premarket; May be Attributed to Novartis Deal with Aduro Biotech,2015-03-30 07:23:00-04:00,ADXS,positive
31651.0,Advaxis Reports First Patient Treated in Phase 1/2 Dose-Escalation Study of ADXS-HPV for Recurrent Cervical Cancer,2015-03-19 07:31:00-04:00,ADXS,negative
31652.0,"Advaxis Offers Prelim. Data from Phase 1/2 Trial of ADXS-HPV in HPV-Associated Anal Cancer in Combo with Chemoradiation, Shows Complex Response, No Recurrences to Date",2015-03-16 07:31:00-04:00,ADXS,negative
31653.0,Advaxis' Gynecologic Oncology Group Unit Begins Enrollment In Stage 2 Of GOG-0265 Clinical Trial,2015-03-11 07:34:00-04:00,ADXS,neutral
31654.0,Advaxis Completes $23M Financing,2015-02-18 12:26:00-05:00,ADXS,neutral
31655.0,Advaxis Spikes to High on Volume,2015-02-18 12:25:00-05:00,ADXS,neutral
31656.0,Advaxis Appoints Mayo Pujols VP Manufacturing,2015-02-13 10:31:00-05:00,ADXS,neutral
31657.0,Morning Market Gainers,2015-02-11 09:48:00-05:00,ADXS,neutral
31658.0,"Advaxis, Incyte Collaborate to Evaluate Investigational Combination of Cancer Immunotherapies for Early Stage Cervical Cancer",2015-02-11 07:32:00-05:00,ADXS,negative
31659.0,Advaxis Reports Formation of Clinical Trial Deal with Incyte to Evaluate Investigational Combo of Two Novel Cancer Immunotherapies,2015-02-11 07:32:00-05:00,ADXS,negative
31660.0,UPDATE: Advaxis Shares Rise 10% Premarket on Update Related to Phase 2 Open-label Clinical Study of ADXS-HPV in Patients With Persistent or Recurrent Cervical Cancer,2015-01-28 08:29:00-05:00,ADXS,negative
31661.0,Advaxis Shares Rise ~20% on Positive Adam F Street.com Article,2015-01-27 10:59:00-05:00,ADXS,positive
31662.0,Adam Feuerstein @adamfeuerstein $ADXS Tweet: Legit Reasons to Take Another Look at Under-Appreciated Cancer Immunotherapy thestreet.com/story/13024047… via @TheStreet,2015-01-27 09:59:00-05:00,ADXS,negative
31663.0,Advaxis Spikes to High on Volume,2015-01-27 09:55:00-05:00,ADXS,neutral
31664.0,Advaxis Announces FDA Acceptance Of Its Investigational New Drug Application To Commence First-In-Human Clinical Trials Of ADXS-HER2,2015-01-22 11:02:00-05:00,ADXS,positive
31665.0,H.C. Wainwright's 8 Healthcare Stock Picks,2015-01-13 07:08:00-05:00,ADXS,neutral
31666.0,Advaxis Submits Investigational New Drug Application to FDA for ADXS-HER2,2015-01-05 07:33:00-05:00,ADXS,neutral
31667.0,"Monday's #PreMarket Movers: Caesars, Enta, Twitter And More",2014-12-22 09:06:00-05:00,ADXS,neutral
31668.0,Advaxis Completes $17M Financing,2014-12-19 15:37:00-05:00,ADXS,neutral
31669.0,Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated Cancers,2014-12-15 07:32:00-05:00,ADXS,positive
31670.0,Advaxis Announces FDA Acceptance of Investigational NDA to Begin Clinical Trials of ADXS-PSA in Combo with Merck's KEYTRUDA(R),2014-12-08 07:32:00-05:00,ADXS,positive
31671.0,Advaxis Announces FDA Acceptance Of Its Investigational New Drug Application To Commence Clinical Trials Of ADXS-PSA In Combination With Merck's KEYTRUDA For Prostate Cancer,2014-12-08 07:31:00-05:00,ADXS,negative
31672.0,Advaxis Reports $1.7M Through New Jersey Technology Business Tax (NOL) Program,2014-11-20 07:44:00-05:00,ADXS,neutral
31673.0,Advaxis to Receive $1.7M Through New Jersey Technology Business Tax Program,2014-11-20 07:31:00-05:00,ADXS,neutral
31674.0,Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune's MEDI4736,2014-11-12 07:34:00-05:00,ADXS,neutral
31675.0,UPDATE: Advaxis Submits Investigational New Drug Application For ADXS31-142 (ADXS-PSA),2014-11-05 07:44:00-05:00,ADXS,neutral
31676.0,Advaxis Submits Investigational New Drug Application For ADXS31-142 (ADXS-PSA) ,2014-11-05 07:33:00-05:00,ADXS,neutral
31677.0,Advaxis Appoints David Mauro As Chief Medical Officer,2014-10-20 07:35:00-04:00,ADXS,neutral
31678.0,Advaxis Provides Clinical Update For Phase 1/2 Trial Of ADXS-HPV Immunotherapy Product Candidate In Anal Cancer,2014-10-15 07:31:00-04:00,ADXS,negative
31679.0,"UPDATE: Advaxis Announces Completion of EOP2 Meeting with FDA for ADXS-HPV, for the Treatment of Cervical Cancer ",2014-09-09 07:34:00-04:00,ADXS,negative
31680.0,"Advaxis Offers Clinical Development Update for ADXS-HPV, Says EOP2 Meeting Completed with FDA",2014-09-09 07:34:00-04:00,ADXS,neutral
31681.0,"Winners & Losers From Monday, August 25",2014-08-26 07:48:00-04:00,ADXS,negative
31682.0,US Stock Futures Rise Ahead Of Economic Data,2014-08-25 07:28:00-04:00,ADXS,neutral
31683.0," Advaxis, Merck to Collaborate on Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer",2014-08-25 05:26:00-04:00,ADXS,negative
31684.0,"UPDATE: Advaxis Deal with UofP Eliminates Milestone Payment Due at Commencement of Phase 3 Trial, Modified to First Regulatory Approval, Penn Will Receive Milestone When Cumulative Global Sales Hit $250M-$2B",2014-07-29 07:40:00-04:00,ADXS,positive
31685.0,"Advaxis, University of Pennsylvania Amend License Agreement ",2014-07-29 07:34:00-04:00,ADXS,positive
31686.0,Advaxis Announces Renewal of Agreement with Upenn,2014-07-29 07:32:00-04:00,ADXS,positive
31687.0,Advaxis Receives Notice of Allowance for Cancer Immunotherapies Patent in Japan ,2014-07-28 07:31:00-04:00,ADXS,negative
31688.0,"US Stock Futures Up Ahead Of McDonald's, Coca-Cola Earnings",2014-07-22 07:34:00-04:00,ADXS,neutral
31689.0,"Advaxis, MedImmune Partner on Immuno-Oncology Combination Clinical Trial ",2014-07-22 05:27:00-04:00,ADXS,neutral
31690.0,Advaxis Announces USDA Filling for ADXS-CHER2,2014-07-02 07:31:00-04:00,ADXS,neutral
31691.0,Advaxis Announces Will Be Added to Russell Microcap Index,2014-06-25 08:35:00-04:00,ADXS,neutral
31692.0,Advaxis Receives Notice of Allowance from US PTO for Two Patent Applications with Multiple Claims Covering Its Cancer Immunotherapy ADXS-cHER2,2014-06-23 07:31:00-04:00,ADXS,negative
31693.0,Advaxis Recieves Approval For a Phase 1/2 Trail Of ADXS-HPV For Higher Doses,2014-06-16 08:32:00-04:00,ADXS,positive
31694.0,Advaxis Announces EOP2 Meeting with FDA has been Granted,2014-06-10 06:33:00-04:00,ADXS,positive
31695.0,Advaxis Says Will Host Business Update Conference Call on Jun. 10th,2014-06-09 07:36:00-04:00,ADXS,neutral
31696.0,Advaxis Announces Positive Results From ADXS-cHER2 Trial,2014-06-06 07:30:00-04:00,ADXS,positive
31697.0,Advaxis Reports Preclinical Study of LM-LLO Immunotherapy Showed Tumor Eradication,2014-06-04 08:04:00-04:00,ADXS,negative
31698.0,Advaxis Reports Promising Phase 2 Data for ADXS-HPV in Women with Recurrent Cervical Cancer at ASCO,2014-05-31 07:59:00-04:00,ADXS,negative
31699.0,Advaxis Announces Has Selected Inventiv Health for Clinical Trials of Immunotherapy Candidates,2014-05-29 07:32:00-04:00,ADXS,neutral
31700.0,Morning Market Movers ,2014-05-27 09:39:00-04:00,ADXS,neutral
31701.0,UPDATE: Advaxis's HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma,2014-05-27 07:33:00-04:00,ADXS,neutral
31702.0,Advaxis Her2 Immunotherapy Gets Orphan Status,2014-05-27 07:31:00-04:00,ADXS,neutral
31703.0,FDA Reports Orphan Drug Designation for Advaxis' Osteosarcoma Treatment,2014-05-23 14:07:00-04:00,ADXS,neutral
31704.0,Advaxis Will Initiate Clinical Development of ADXS-cHER2,2014-05-05 07:32:00-04:00,ADXS,neutral
31705.0,UPDATE: Advaxis Granted FDA Orphan Drug Designation for Treatment of Invasive Cervical Cancer ,2014-05-01 07:39:00-04:00,ADXS,negative
31706.0,Advaxis Receives FDA Orphan Drug Designation for Treatment Of Invasive Cervical Cancer,2014-05-01 07:37:00-04:00,ADXS,negative
31707.0,UPDATE: Advaxis Reports Japanese Patent Officer Has Granted Notice of Allowance for Two Patent Apps Covering Cancer Immunotherapy Platform Technology,2014-04-14 07:39:00-04:00,ADXS,negative
31708.0,Advaxis Reports Japanese Patent Officer Has Granted Notice of Allowance for Two Patent Apps Covering Cancer Immunotherapy Platform Technology,2014-04-14 07:33:00-04:00,ADXS,negative
31709.0,Filing from Advaxis Shows Co. Has Postponed Annual Shareholder Meeting from Apr. 25th to Jul. 9th,2014-04-08 16:10:00-04:00,ADXS,negative
31710.0,UPDATE: Advaxis Receives Notice of Allowance From U.S. Patent and Trademark Office for Three Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy Platform Technology,2014-04-01 07:33:00-04:00,ADXS,negative
31711.0,Advaxis Announces Notice of Allowance from US PTO for Three Patent Applications Covering Cancer Immunotherapy Platform Technology,2014-04-01 07:31:00-04:00,ADXS,negative
31712.0,"Advaxis Announces Closing of Public Offering of Common Stock, Collects $14.07M in Gross Proceeds",2014-03-31 16:32:00-04:00,ADXS,negative
31713.0,Morning Market Losers ,2014-03-27 09:50:00-04:00,ADXS,negative
31714.0,Advaxis Prices 4.08M Share Offering at $3.00/Share,2014-03-26 21:39:00-04:00,ADXS,positive
31715.0,UPDATE: Advaxis Announces Proposed Public Offering of Common Stock,2014-03-26 16:09:00-04:00,ADXS,neutral
31716.0,Advaxis Announces Public Offering of Common Stock,2014-03-26 16:08:00-04:00,ADXS,neutral
31717.0,"Advaxis Announces CFO Has Left Co., Sara Bonstein Named as Replacement",2014-03-24 17:19:00-04:00,ADXS,neutral
31718.0,"Aratana, Advaxis Announce Exclusive Global Licensing Agreement ",2014-03-19 20:04:00-04:00,ADXS,positive
31719.0,Morning Market Movers ,2014-03-18 09:38:00-04:00,ADXS,neutral
31720.0,Advaxis Receives Patent in Japan for ADXS-HPV for the Treatment of Cervical Cancer,2014-03-18 07:31:00-04:00,ADXS,negative
31721.0,"Advaxis, UC San Francisco to Evaluate Cancer Immunotherapy Constructs in Prostate Cancer ",2014-03-17 07:32:00-04:00,ADXS,negative
31722.0,Biocon Collaborates With Advaxis For 'ADXS-HPV',2014-01-22 09:30:00-05:00,ADXS,neutral
31723.0,Advaxis Doses First Patient in Phase 1/2 Head and Neck Cancer Study ,2014-01-21 07:35:00-05:00,ADXS,negative
31724.0,Benzinga Weekly Preview: Markets Take A Breather For The Holidays,2013-12-20 16:48:00-05:00,ADXS,positive
31725.0,Advaxis Signs License Agreement for Development and Commercialization of ADXS-HPV in Asia ,2013-12-09 07:32:00-05:00,ADXS,positive
31726.0,Advaxis Canine Cancer Vaccine Featured on ABC News ,2013-11-22 08:47:00-05:00,ADXS,negative
31727.0,"Advaxis Says 18-Month Survival Data Increased from 22% to 28%, Saw Tumor Response Rate 11% Similar in Both Groups",2013-11-08 08:36:00-05:00,ADXS,negative
31728.0,Advaxis Spikes Higher on FDA Orphan Designation for Live Attenuated Bioengineered Listeria Monocytogenes Immunotherapy,2013-11-04 11:03:00-05:00,ADXS,neutral
31729.0,"Advaxis Shares Off Highs, Company Announced Tuesday a Securities Purchase Agreement with JMJ Financial",2013-09-11 10:51:00-04:00,ADXS,positive
31730.0,"Advaxis Requests Orphan Drug Status for Treatment of HPV-Associated Head, Neck Cancer with ADXS-HPV",2013-06-11 08:02:00-04:00,ADXS,negative
31731.0,Advaxis Announces Withdrawal of Proxy Statement Bid to Amend Incentive Plan,2013-06-06 08:08:00-04:00,ADXS,positive
31732.0,"Benzinga's Microcap Movers for Wednesday June 13, 2012",2012-06-14 07:18:00-04:00,ADXS,neutral
31733.0,Advaxis Receives Additional Financing,2011-12-30 09:31:00-05:00,ADXS,neutral
31734.0,Advaxis Reports Preliminary Data from ADXS-HPV Phase 2 Trial in Patients with Recurrent/Refractory Cervical Cancer at AACR,2011-12-16 09:00:00-05:00,ADXS,negative
31735.0,"Advaxis Granted Pre-IND Meeting with FDA for ADXS-HER2, an Immunotherapy for HER2 Expressing Cancers",2011-10-11 13:18:00-04:00,ADXS,positive
31736.0,Advaxis Granted Pre-IND Meeting with the FDA for Advaxis-PSA Prostate Immunotherapy ,2011-06-30 09:03:00-04:00,ADXS,positive
